Sign up
Pharma Capital

Admedus appoints Steve Denaro to the board

The company has developed heart valve technology and has an immunotherapy business.
empty board room seats
Shares in the company last traded at 13.5 cents

Admedus Ltd (ASX:AHZ) has appointed experienced tax professional Streve Denaro to sit on its board as a non-executive director and company secretary.

The chartered accountant and registered tax agent has more than 30 years of senior and board level experience across publicly listed companies serving at CFO, director and company secretary.

Admedus’s chairman John Seaberg said: “We are very pleased to welcome Steve to the Admedus board.

“His comprehensive experience in financial management and deep understanding of the Australian and global financial regulatory environments make him a valuable addition to the company’s leadership as we pursue exciting new strategic opportunities.”

READ: Admedus completes placement to strategic cornerstone investor Star Bright Group

Substantial investor, Star Bright Holding Ltd and its associated companies recently increased its shareholding to 19.99%.

The ownership is a result of participation in 2018 capital raisings which came in the form of share placements.

Admedus is also negotiating with Star Bright in respect of a long-term funding agreement for Admedus Immunotherapies.

The two parties entered a memorandum of understanding (MoU) for a 60% share of the vaccines business for an initial investment of $18 million.

View full AHZ profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.